You have free access to this content

Cancer

Cover image for Vol. 117 Issue 13

1 July 2011

Volume 117, Issue 13

Pages 2827–3060

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Erratum
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Erratum
    1. You have free access to this content
      Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer (pages 2830–2832)

      Jeffrey M. Holzbeierlein

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25899

      High-risk prostate cancer can be treated effectively with radical prostatectomy. However, monotherapy rarely results in a cure. See referenced original article on pages, this issue.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      Impact of neoadjuvant chemotherapy on breast reconstruction (pages 2833–2841)

      Yue-Yung Hu, Christine M. Weeks, Haejin In, Christopher M. Dodgion, Mehra Golshan, Yoon S. Chun, Michael J. Hassett, Katherine A. Corso, Xiangmei Gu, Stuart R. Lipsitz and Caprice C. Greenberg

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25872

      Cosmesis after mastectomy has assumed a pivotal role in patient and provider decision making, and multiple studies have confirmed the safety of both chemotherapy before breast surgery and immediate reconstruction. The current results indicated that administering neoadjuvant chemotherapy decreases the likelihood of undergoing immediate reconstruction but does not significantly increase the rate of delayed reconstruction.

    2. You have free access to this content
      miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met (pages 2842–2852)

      Zheng-sheng Wu, Qiang Wu, Chao-qun Wang, Xiao-nan Wang, Jing Huang, Jing-jing Zhao, Shan-shan Mao, Gui-hong Zhang, Xiao-chun Xu and Nong Zhang

      Article first published online: 10 JAN 2011 | DOI: 10.1002/cncr.25860

      The authors found that miR-340 expression may be a useful biomarker for detecting breast cancer and predicting survival of breast cancer patients. These data will guide future studies of microRNA function in breast cancer.

    3. Gastrointestinal Disease
      You have free access to this content
      Do patients consider preoperative chemoradiation for primary rectal cancer worthwhile? (pages 2853–2862)

      Erin D. Kennedy, Selina Schmocker, Charles Victor, Nancy N. Baxter, John Kim, James Brierley and Robin S. McLeod

      Article first published online: 10 JAN 2011 | DOI: 10.1002/cncr.25842

      The results from this study indicated that 54% of future patients with rectal cancer would not choose preoperative chemoradiation unless it decreased their baseline risk of local recurrence from 15% to 5% (ie, an absolute risk reduction ≥10%). These findings suggested that patient preferences may not be consistent with current published guidelines and that preoperative chemoradiation should be considered as an option rather than a guideline.

    4. You have free access to this content
      Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival (pages 2863–2872)

      Donghui Li, Motofumi Tanaka, F. Charles Brunicardi, William E. Fisher, Richard A Gibbs and Marie-Claude Gingras

      Article first published online: 10 JAN 2011 | DOI: 10.1002/cncr.25858

      Associations were observed between somatostatinreceptor 5 (SSTR5) genotypes and pancreatic cancer risk. Weak associations with overall survival were also observed. These findings suggest that the SSTR5 gene played a role in pancreatic cancer.

    5. Genitourinary Disease
      You have free access to this content
      Survival after complete surgical resection of multiple metastases from renal cell carcinoma (pages 2873–2882)

      Angela L. Alt, Stephen A. Boorjian, Christine M. Lohse, Brian A. Costello, Bradley C. Leibovich and Michael L. Blute

      Article first published online: 10 JAN 2011 | DOI: 10.1002/cncr.25836

      Complete metastasectomy was associated with a significant prolongation of both median cancer-specific survival (4.8 years vs 1.3 years; P < .001) and overall survival (4.0 years vs 1.3 years; P < .001) for patients who had multiple metastases from renal cell carcinoma. The benefit from complete resection was evident in patients with lung-only and nonlung-only disease and was maintained after controlling for patient performance status and disease burden.

    6. You have free access to this content
      Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer (pages 2883–2891)

      Stephen A. Boorjian, R. Jeffrey Karnes, Rosalia Viterbo, Laureano J. Rangel, Eric J. Bergstralh, Eric M. Horwitz, Michael L. Blute and Mark K. Buyyounouski

      Article first published online: 10 JAN 2011 | DOI: 10.1002/cncr.25900

      Radical prostatectomy (RRP) and external-beam radiation therapy (EBRT) plus androgen-deprivation therapy (ADT) provided similar long-term cancer control for patients with high-risk prostate cancer, although the risk of all-cause mortality was greater after EBRT plus ADT than after RRP. The authors concluded that continued investigation into the differing impact of treatments on quality-of-life measures and noncancer mortality will be necessary to determine the optimal management approach for these patients.

    7. You have free access to this content
      Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology : A decision-curve analysis (pages 2892–2897)

      Shahrokh F. Shariat, Caroline Savage, Thomas F. Chromecki, Maxine Sun, Douglas S. Scherr, Richard K. Lee, Giovanni Lughezzani, Mesut Remzi, Michael J. Marberger, Pierre I. Karakiewicz and Andrew J. Vickers

      Article first published online: 10 JAN 2011 | DOI: 10.1002/cncr.25903

      Nuclear matrix protein 22 (NMP22) measured in urine can help predict the result of cystoscopy in patients who receive surveillance for a history of nonmuscle-invasive bladder cancer. The current results indicated that decisions regarding immediate versus deferred cystoscopy on the basis of NMP22 are likely to lead to better patient outcomes than performing cystoscopy in everyone or using age and sex alone to select patients for cytoscopy.

    8. Head and Neck Disease
      You have free access to this content
      CpG island methylation profiling in human salivary gland adenoid cystic carcinoma (pages 2898–2909)

      Achim Bell, Diana Bell, Randal S. Weber and Adel K. El-Naggar

      Article first published online: 11 JAN 2011 | DOI: 10.1002/cncr.25818

      CpG island methylation profiling of human salivary gland adenoid cystic carcinoma from 16 patients provided 34 hypermethylated and 7 hypomethylated genes, consistently aberrantly methylated in all 16 tumors, with EN1 hypermethylation as a possible biomarker candidate.

    9. You have free access to this content
      Intensity-modulated radiation therapy reduces radiation-induced trismus in patients with nasopharyngeal carcinoma : A prospective study with >5 years of follow-up (pages 2910–2916)

      Yuan-Yuan Chen, Chong Zhao, Jin Wang, Hong-Lian Ma, Shu-Zheng Lai, Yuan Liu, Fei Han, Li-Xia Lu, Yong Bao and Ming Chen

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25773

      This large, single-arm measurement study with long-term follow-up indicated that intensity-modulated radiation therapy reduced the irradiation dose to the temporomandibular joint, which likely reduced the incidence and severity of radiation-induced trismus after radiotherapy.

    10. You have free access to this content
      Nodal yield and survival in oral squamous cancer : Defining the standard of care (pages 2917–2925)

      Ardalan Ebrahimi, Wan J. Zhang, Kan Gao and Jonathan R. Clark

      Article first published online: 18 JAN 2011 | DOI: 10.1002/cncr.25834

      This is the first study to demonstrate that in patients undergoing elective neck dissection for oral squamous cancer, nodal yield is an independent predictor of reduced overall, disease-specific, and disease-free survival after adjusting for potential confounding factors. The results suggest that an adequate lymphadenectomy in this setting should include at least 18 nodes to appropriately stage and adequately treat the neck.

    11. You have free access to this content
      Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells (pages 2926–2938)

      Vlad C. Sandulache, Thomas J. Ow, Curtis R. Pickering, Mitchell J. Frederick, Ge Zhou, Izabela Fokt, Melinda Davis-Malesevich, Waldemar Priebe and Jeffrey N. Myers

      Article first published online: 10 JAN 2011 | DOI: 10.1002/cncr.25868

      The results from this study indicated that glucose catabolism drives head and neck cancer energy production and survival. Loss of wild-type p53 perturbed energy balance and altered survival during nutrient starvation.

    12. You have free access to this content
      Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck (pages 2939–2950)

      Nikolina Vlatković, Ashraf El-Fert, Timothy Devling, Arpita Ray-Sinha, David M. Gore, Carlos P. Rubbi, Andy Dodson, Andrew S. Jones, Tim R. Helliwell, Terence M. Jones and Mark T. Boyd

      Article first published online: 10 JAN 2011 | DOI: 10.1002/cncr.25864

      This is the first description and analysis of MTBP expression in human cancer, and we have used this in combination with 2 other well established biomarkers, p53 and MDM2, to determine whether combinatorial analysis of these may provide predictive information for patients with head and neck cancer. Our data indicate that loss of MTBP expression is significantly associated with reduced survival in patients expressing high p53 and low MDM2 (likely to have p53 mutations).

    13. Hepatobiliary Disease
      You have free access to this content
      A clustered ground-glass hepatocyte pattern represents a new prognostic marker for the recurrence of hepatocellular carcinoma after surgery (pages 2951–2960)

      Hung-Wen Tsai, Yih-Jyh Lin, Pin-Wen Lin, Han-Chieh Wu, Kai-Hsi Hsu, Chia-Jui Yen, Shih-Huang Chan, Wenya Huang and Ih-Jen Su

      Article first published online: 10 JAN 2011 | DOI: 10.1002/cncr.25837

      Assessment of ground-glass hepatocyte (GGH) patterns or hepatitis B surface antigen expression in nontumorous liver samples provided an easily recognized, new risk marker for the recurrence of hepatitis B virus-related hepatocellular carcinoma after hepatic resection.

    14. Lung Disease
      You have free access to this content
      Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer (pages 2961–2969)

      Mary E. Cooley, Karen M. Emmons, Robert Haddad, Qian Wang, Marshall Posner, Raphael Bueno, Tiffany-Jen Cohen and Bruce E. Johnson

      Article first published online: 10 JAN 2011 | DOI: 10.1002/cncr.25828

      Continued smoking after a diagnosis of cancer is associated with adverse effects. The results from this study indicated that, because only 50% of smokers with cancer are interested in a smoking-cessation program, innovative approaches to increase demand for, access to, and use of smoking-cessation programs need to be developed and tested in this population.

    15. You have free access to this content
      Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells (pages 2970–2985)

      Han-Shui Hsu, Pin-I Huang, Yuh-Lih Chang, Ching Tzao, Yi-Wei Chen, Hsin-Chin Shih, Shih-Chieh Hung, Yu-Chih Chen, Ling-Ming Tseng and Shih-Hwa Chiou

      Article first published online: 10 JAN 2011 | DOI: 10.1002/cncr.25869

      The current results indicated that the signal transducer and activator of transcription 3 (STAT3) signaling axis may be responsible for the cancer stem cell-like properties and radioresistance of prominin-1 (CD133)-positive nonsmall cell lung cancer (NSCLC) cells. Targeting STAT3 signaling by using cucurbitacin I may suppress tumorigenicity and enhance chemoradiotherapy response in patients who have CD133-positive NSCLC.

    16. You have free access to this content
      Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab : The NEAR trial (pages 2986–2994)

      Alexandra D. Jensen, Marc W. Münter, Helge G. Bischoff, Renate Haselmann, Uwe Haberkorn, Peter E. Huber, Michael Thomas, Jürgen Debus and Klaus K. Herfarth

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25888

      The aim of this study was to evaluate efficacy and toxicity of radioimmunotherapy with intensity-modulated radiation (IMRT) and cetuximab in stage III nonsmall cell lung cancer. Radioimmunotherapy with cetuximab for stage III nonsmall cell lung cancer was safe and feasible, especially in elderly patients with multiple comorbidities.

    17. You have free access to this content
      Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy : Single-Institution Experience in 600 Patients (pages 2995–3003)

      Branislav Jeremić, Biljana Miličić and Slobodan Milisavljevic

      Article first published online: 10 JAN 2011 | DOI: 10.1002/cncr.25910

      Multivariate analysis of prognostic factors in patients with stage III nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy was investigated. Only age did not influence any of endpoints, whereas female sex, lower Karnofsky performance score, less pronounced weight loss, lower stage, squamous histology, shorter interfraction interval, and treatment independently predicted better overall survival and local progression-free survival; treatment and histology did not influence distant metastasis-free survival.

    18. You have free access to this content
      Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer (pages 3004–3013)

      Samir Sejpal, Ritsuko Komaki, Anne Tsao, Joe Y. Chang, Zhongxing Liao, Xiong Wei, Pamela K. Allen, Charles Lu, Michael Gillin and James D Cox

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25848

      This preliminary study on the use of proton beam therapy for non-small cell lung cancer indicated that this treatment is less toxic to normal tissues than photon (x-ray) therapy delivered as 3-dimensional conformal or intensity-modulated radiation therapy. A prospective randomized trial comparing proton therapy with intensity-modulated therapy for stage 2/3 lung cancer is currently underway.

    19. Neuro-Oncology
      You have free access to this content
      Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy : European organization for research and treatment of cancer trial 26951 (pages 3014–3026)

      Karima Mokhtari, François Ducray, Johan M. Kros, Thierry Gorlia, Ahmed Idbaih, Martin Taphoorn, Pieter Wesseling, Khe Hoang-Xuan, Martin Van den Bent and Marc Sanson

      Article first published online: 18 JAN 2011 | DOI: 10.1002/cncr.25827

      The expression of alpha-internexin (INA), a proneural marker that is correlated with the 1p19q codeletion, was investigated in patients who were enrolled in the European Organization for Research and Treatment of Cancer 26951 trial (radiotherapy with or without chemotherapy in patients anaplastic oligodendroglial tumors). The results indicated that INA expression predicted prolonged survival and progression-free survival in both arms, even in patients without the 1p19q codeletion, and also may have a positive impact on the efficacy of combined radiotherapy plus procarbazine, lomustine, and vincristine chemotherapy.

    20. Sarcoma
      You have free access to this content
      Clinical features and outcomes in patients with extraskeletal ewing sarcoma (pages 3027–3032)

      Mark A. Applebaum, Jennifer Worch, Katherine K. Matthay, Robert Goldsby, John Neuhaus, Daniel C. West and Steven G. DuBois

      Article first published online: 10 JAN 2011 | DOI: 10.1002/cncr.25840

      Patient and tumor characteristics in Ewing sarcoma differ between extraskeletal compared with skeletal origin. Overall survival is superior in patients with extraskeletal Ewing sarcoma.

    21. Discipline

      Outcomes Research
      You have free access to this content
      Occupational outcomes of adult childhood cancer survivors : A report from the childhood cancer survivor study (pages 3033–3044)

      Anne C. Kirchhoff, Kevin R. Krull, Kirsten K. Ness, Elyse R. Park, Kevin C. Oeffinger, Melissa M. Hudson, Marilyn Stovall, Leslie L. Robison, Thomas Wickizer and Wendy Leisenring

      Article first published online: 18 JAN 2011 | DOI: 10.1002/cncr.25867

      Adult childhood cancer survivors are employed in lower-skill jobs than their siblings. Female survivors and survivors with a history of cranial radiation are at particular risk.

    22. Psychosocial Oncology
      You have free access to this content
      Minimal social network effects evident in cancer screening behavior (pages 3045–3052)

      Nancy L. Keating, A. James O'Malley, Joanne M. Murabito, Kirsten P. Smith and Nicholas A Christakis

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25849

      We assessed whether screening for breast, prostate, or colorectal cancer is influenced by the actual screening behaviors of siblings, friends, spouses, and coworkers. Aside from a slight increase in breast cancer screening among women whose sisters were screened and colorectal cancer screening if spouses were screened, the screening behavior of siblings, friends, or coworkers did not influence cancer screening behaviors.

    23. Radiation Oncology
      You have free access to this content
      The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial (pages 3053–3059)

      David A. Bush, Zeid Kayali, Roger Grove and Jerry D. Slater

      Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25809

      Proton beam therapy was found to be a safe and effective treatment for patients with cirrhosis who had inoperable hepatocellular carcinoma. A randomized, controlled comparison with standard treatment has been underway.

  4. Erratum

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Erratum
    1. You have free access to this content

SEARCH

SEARCH BY CITATION